Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the company has appointed ...

Cardiff has unveiled a new approach to training and retaining doctors in Wales. Marking the biggest transformation of Cardiff University's medical education programme since its School of Medicine was ...

Shares of Cardiff Oncology (NASDAQ:CRDF) lost ~11% in the post-market trading on Tuesday after the cancer drug developer appointed a new chief medical officer ahead of a crucial mid-stage trial ...

Cardiff and NMS have agreed to a full and mutual release of all claims asserted in the litigation pending in the U.S. District Court for the Southern District of California. Cardiff and NMS plan to ...

Cardiff Oncology, Inc. ( CRDF) and Nerviano Medical Sciences S.r.l. announced that they have settled their licensing dispute over onvansertib, Cardiff's lead drug candidate, amended their 2017 ...

Cardiff Oncology (CRDF) said late Tuesday it has named Roger Sidhu as chief medical officer, succeeding Fairooz Kabbinavar, who will retain an advisory role at the company. Sidhu was most recently ...

The number of students applying to Wales’ two medical schools is rising - but only a fraction of those are being offered places. Less than half of those from Wales applying to Cardiff University ...